On April 27, 2026 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER growth. Adjusted diluted EPS are expected to be $0.54 on a reported basis and $0.54 CER, in line with the outlook.

QIAGEN’s growth pillars together grew 4% CER compared to Q1 2025. Sample technologies delivered 9% CER growth compared with Q1 2025, and 3% CER growth excluding the Parse acquisition, supported by demand for automated consumables and instrument placements. QIAcuity digital PCR delivered double-digit CER sales growth on higher consumables and instrument sales over the year-ago period. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. QIAstat-Dx sales declined 1% CER as expected against tough prior-year results. Consumables sales rose despite a weaker respiratory season on double-digit CER growth from recently launched Gastrointestinal and Meningitis panels in the U.S., while instrument placements continued at a good level.

QuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East. Trends remained solid in other patient testing groups. QIAGEN now expects QuantiFERON full-year 2026 sales to be unchanged at CER compared with 2025 sales of $503 million.

QIAGEN has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include headwinds from reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER). QIAGEN expects stronger growth trends in the second half of 2026, supported by the end of headwinds from the discontinuation of NeuMoDx and Dialunox, benefits from recent and planned product launches, sequential improvement in QuantiFERON sales and contributions from the Parse acquisition tracking ahead of the original target for 2026.

For Q2 2026, QIAGEN expects net sales to decline approximately 2% CER from $534 million in Q2 2025. Adjusted diluted EPS are expected to be at least $0.60 CER compared with $0.60 in Q2 2025.

"QIAGEN made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies, QIAcuity and QIAGEN Digital Insights," said Thierry Bernard, Chief Executive Officer of QIAGEN. "QuantiFERON was affected by the significant decline in immigration testing demand, but we view this as a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing. We are focused on executing against our updated 2026 targets and positioning QIAGEN for faster growth in the second half of 2026."

"Our profitability for the first quarter reflected disciplined execution in a challenging environment, as we managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements and measures to ensure reliable product supply," said Roland Sackers, Chief Financial Officer of QIAGEN. "We are focused on delivering solid profitable growth through efficiency gains combined with disciplined capital allocation and targeted investments that strengthen QIAGEN’s long-term growth potential and create value for shareholders."

Preliminary sales by product groups

In $ millions

Q1

2026

sales

2025

sales

Change

CER change

Sample technologies

170

150

+13 %

+9 %

Diagnostic solutions

185

187

-1 %

-4 %

Of which QuantiFERON

113

116

-3 %

-5 %

Of which QIAstat-Dx

36

34

+4 %

-1 %

Of which NeuMoDx

—

6

-100 %

-100 %

Of which Other

36

31

+19 %

+15 %

PCR/Nucleic acid amplification

69

76

-9 %

-13 %

Genomics/NGS

57

53

+6 %

+4 %

Other

12

18

-31 %

-31 %

Total net sales

492

483

+2 %

-1 %

Tables may have rounding differences. Percentage changes are to prior-year periods.

Preliminary Q1 2026 results conference call on Tuesday, April 28, 2026

A conference call to discuss the preliminary Q1 2026 results and updated full-year 2026 outlook is scheduled for Tuesday, April 28, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. A live audio webcast will be available in the Investor Relations section of the QIAGEN website (www.qiagen.com), with a recording accessible after the event. The accompanying presentation will be published at the same time as this press release under "Events and Presentations" in the same section.

Full Q1 2026 results publication on May 6, 2026

QIAGEN plans to publish full Q1 2026 results on May 6, 2026, shortly after 22:05 Frankfurt Time / 21:05 London Time / 16:05 New York Time.

QuantiFERON Spotlight Session on May 7, 2026

As previously announced, QIAGEN plans to hold a virtual Spotlight Session to provide insights into our strategic priorities for QuantiFERON and an update on the latest product enhancements. The online event, which is a new format that builds on the recent Deep Dives series, is scheduled for Thursday, May 7, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. Registration details and further information about the webcast are available in the Investor Relations section of the QIAGEN website (www.qiagen.com), under Events and Presentations (View Source), with a recording accessible after the event.

(Press release, Qiagen, APR 27, 2026, View Source [SID1234664808])